Clinical Cancer Research Targets Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Talantov, D.
Right arrow Articles by Wang, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Talantov, D.
Right arrow Articles by Wang, Y.
Clinical Cancer Research Vol. 11, 7234-7242, October 15, 2005
© 2005 American Association for Cancer Research


Human Cancer Biology

Novel Genes Associated with Malignant Melanoma but not Benign Melanocytic Lesions

Dmitri Talantov, Abhijit Mazumder, Jack X. Yu, Thomas Briggs, Yuqiu Jiang, John Backus, David Atkins and Yixin Wang

Authors' Affiliation: Veridex, LLC, a Johnson & Johnson Company, San Diego, California

Requests for reprints: Yixin Wang, Veridex, LLC, a Johnson & Johnson Company, 3210 Merryfield Row, San Diego, CA 92121. Phone: 858-784-3295; Fax: 858-450-2070; E-mail: ywang{at}vrxus.jnj.com.

Purpose: Cutaneous melanoma is a common, aggressive cancer with increasing incidence. The identification of melanoma-specific deregulated genes could provide molecular markers for lymph node staging assays and further insight into melanoma tumorigenesis.

Experimental Design: Total RNA isolated from 45 primary melanoma, 18 benign skin nevi, and 7 normal skin tissue specimens were analyzed on an Affymetrix Hu133A microarray containing 22,000 probe sets.

Results: Hierarchical clustering revealed a distinct separation of the melanoma samples from the benign and normal specimens. Novel genes associated with malignant melanoma were identified. Differential gene expression of two melanoma-specific genes, PLAB and L1CAM, were tested by a one-step quantitative reverse transcription-PCR assay on primary malignant melanoma, benign nevi, and normal skin samples, as well as on malignant melanoma lymph node metastasis and melanoma-free lymph nodes. The performance of the markers was compared with conventional melanoma markers such as tyrosinase, gp100, and MART1.

Conclusion: Our study systematically identified novel melanoma-specific genes and showed the feasibility of using a combination of PLAB and L1CAM in a reverse transcription-PCR assay to differentiate clinically relevant samples containing benign or malignant melanocytes.




This article has been cited by other articles:


Home page
Am. J. Pathol.Home page
H. Yu, R. McDaid, J. Lee, P. Possik, L. Li, S. M. Kumar, D. E. Elder, P. Van Belle, P. Gimotty, M. Guerra, et al.
The Role of BRAF Mutation and p53 Inactivation during Transformation of a Subpopulation of Primary Human Melanocytes
Am. J. Pathol., June 1, 2009; 174(6): 2367 - 2377.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
M. Barradas, E. Anderton, J. C. Acosta, S. Li, A. Banito, M. Rodriguez-Niedenfuhr, G. Maertens, M. Banck, M.-M. Zhou, M. J. Walsh, et al.
Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS
Genes & Dev., May 15, 2009; 23(10): 1177 - 1182.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
J. M. Hilari, C. Mangas, L. Xi, C. Paradelo, C. Ferrandiz, S. J. Hughes, C. Yueh, I. Altomare, W. E. Gooding, and T. E. Godfrey
Molecular Staging of Pathologically Negative Sentinel Lymph Nodes from Melanoma Patients Using Multimarker, Quantitative Real-Time RT-PCR
Ann. Surg. Oncol., January 1, 2009; 16(1): 177 - 185.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. D. Da Forno, J. H. Pringle, P. Hutchinson, J. Osborn, Q. Huang, L. Potter, R. A. Hancox, A. Fletcher, and G. S. Saldanha
WNT5A Expression Increases during Melanoma Progression and Correlates with Outcome
Clin. Cancer Res., September 15, 2008; 14(18): 5825 - 5832.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. W.J. van Kilsdonk, R. H. Wilting, M. Bergers, G. N.P. van Muijen, J. Schalkwijk, L. C.L.T. van Kempen, and G. W.M. Swart
Attenuation of Melanoma Invasion by a Secreted Variant of Activated Leukocyte Cell Adhesion Molecule
Cancer Res., May 15, 2008; 68(10): 3671 - 3679.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. R. Moore, D. L. Persons, J. A. Sosman, D. Bobadilla, V. Bedell, D. D. Smith, S. R. Wolman, R. J. Tuthill, J. Moon, V. K. Sondak, et al.
Detection of Copy Number Alterations in Metastatic Melanoma by a DNA Fluorescence In situ Hybridization Probe Panel and Array Comparative Genomic Hybridization: A Southwest Oncology Group Study (S9431)
Clin. Cancer Res., May 15, 2008; 14(10): 2927 - 2935.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
C. Rolny, L. Capparuccia, A. Casazza, M. Mazzone, A. Vallario, A. Cignetti, E. Medico, P. Carmeliet, P. M. Comoglio, and L. Tamagnone
The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment
J. Exp. Med., May 12, 2008; 205(5): 1155 - 1171.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
M. Bazzaro, A. Santillan, Z. Lin, T. Tang, M. K. Lee, R. E. Bristow, I.-M. Shih, and R. B.S. Roden
Myosin II Co-Chaperone General Cell UNC-45 Overexpression Is Associated with Ovarian Cancer, Rapid Proliferation, and Motility
Am. J. Pathol., November 1, 2007; 171(5): 1640 - 1649.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. B. Axelsen, J. Lotem, L. Sachs, and E. Domany
Genes overexpressed in different human solid cancers exhibit different tissue-specific expression profiles
PNAS, August 7, 2007; 104(32): 13122 - 13127.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
H. Jin, X. Wang, J. Ying, A. H. Y. Wong, Y. Cui, G. Srivastava, Z.-Y. Shen, E.-M. Li, Q. Zhang, J. Jin, et al.
Epigenetic silencing of a Ca2+-regulated Ras GTPase-activating protein RASAL defines a new mechanism of Ras activation in human cancers
PNAS, July 24, 2007; 104(30): 12353 - 12358.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. R. Alonso, L. Tracey, P. Ortiz, B. Perez-Gomez, J. Palacios, M. Pollan, J. Linares, S. Serrano, A. I. Saez-Castillo, L. Sanchez, et al.
A High-Throughput Study in Melanoma Identifies Epithelial-Mesenchymal Transition as a Major Determinant of Metastasis
Cancer Res., April 1, 2007; 67(7): 3450 - 3460.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
L. Packer, S. Pavey, A. Parker, M. Stark, P. Johansson, B. Clarke, P. Pollock, M. Ringner, and N. Hayward
Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN
Carcinogenesis, September 1, 2006; 27(9): 1778 - 1786.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.